<DOC>
	<DOCNO>NCT01340053</DOCNO>
	<brief_summary>This multi-center , Phase 2 , randomize , double-blind , placebo control study RDX5791 subject IBS-C . Patients 18 75 year old , meet definition IBS-C define Rome III Criteria Diagnosis IBS undergo battery screening procedure determine eligibility trial . The study consist 2-week treatment-free screening period , 4-week blind treatment period , 2-week treatment-free follow-up period .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy RDX5791 Treatment Constipation Predominant Irritable Bowel Syndrome ( IBS-C )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subject meet Rome III criterion IBSC If &gt; 50 year old , colonoscopy evaluation within 10 year All age , negative colonoscopy `` warning symptom '' Active disease 2week screening period Compliant IVRS Subjects IBSD , IBSM unsubtyped IBS accord Rome III criterion Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract Use medication know affect stool consistency Subject protocolexcluded clinically significant medical surgical history could confound study assessment prevent completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>